Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Panbela Therapeutics, Inc. (PBLA)
Company Research
Source: GlobeNewswire
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares. Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February 13, 2024, Panbela received a letter from Nasdaq confirming that Panbela has cured the previously identified minimum bid price and the publicly held shares requirements, under Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). The Company will be presenting its plan to the Nasdaq Hearings Panel regarding equity compliance. About Panbela’s PipelineThe pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic
Show less
Read more
Impact Snapshot
Event Time:
PBLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBLA alerts
High impacting Panbela Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PBLA
News
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025 [Yahoo! Finance]Yahoo! Finance
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025GlobeNewswire
- Panbela Announces Poster Presentation at American Association for Cancer Research: [Yahoo! Finance]Yahoo! Finance
- Panbela Announces Poster Presentation at American Association for Cancer Research:GlobeNewswire
- Panbela Announces Transfer to OTCQB MarketGlobeNewswire
PBLA
Earnings
- 3/26/24 - Miss
PBLA
Sec Filings
- 4/26/24 - Form PRER14A
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form 8-K
- PBLA's page on the SEC website